TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Ascentage Pharma Group International ( (HK:6855) ) is now available.
Ascentage Pharma has announced the clearance from the US FDA and EMA for a global Phase III study of olverembatinib in combination with chemotherapy for newly diagnosed Ph+ ALL patients. This study, known as POLARIS-1, aims to accelerate the drug’s registration in the US and Europe and has shown promising efficacy and safety results in early data. The study’s success could significantly impact the treatment landscape for Ph+ ALL, offering a new option for patients with limited current treatments.
The most recent analyst rating on (HK:6855) stock is a Hold with a HK$63.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a pharmaceutical company focused on developing therapies for cancer, particularly targeting drug-resistant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The company is known for its third-generation BCR-ABL inhibitor, olverembatinib, which is approved in China and covered by the China National Reimbursement Drug List.
Average Trading Volume: 2,210,232
Technical Sentiment Signal: Buy
Current Market Cap: HK$23.31B
For an in-depth examination of 6855 stock, go to TipRanks’ Overview page.